Novartis buys Pfizer's Enablex for CHF310.5mm
Novartis AG is adding to its primary care portfolio by acquiring Pfizer's drug Enablex (darifenacin), a treatment for overactive bladder, for CHF310.5mm ($225mm).
- Marketing (Licensing)
- Product Purchase
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.